Exploring Tumor Biology with Fluorodeoxyglucose-Positron Emission Tomography Imaging in Breast Carcinoma

PET Clinics

Volumn 4, Issue 4, 2009, Pages 381-389

  Basu, Sandip ^a   Kumar, Rakesh ^b   Mavi, Ayşe ^c   Alavi, Abass ^d  

^a TATA MEMORIAL HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c YEDITEPE UNIVERSITY   (Turkey)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast carcinoma; FDG positron emission tomography; Triple negative cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; WATER O 15;

BONE METASTASIS; BREAST CARCINOMA; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG RESPONSE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 75349109243     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.12.001     Document Type: Review

References (19)

1. Buck A., Schirrmeister H., Kuhn T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29 (2002) 1317-1323
2. Crippa F., Seregni E., Agresti R., et al. Association between [18F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index, and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25 (1998) 1429-1434
3. Basu S., Chen W., Tchou J., et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112 5 (2008) 995-1000
4. Mavi A., Cermik T.F., Urhan M., et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 48 8 (2007) 1266-1272
5. Basu S., Mavi A., Cermik T., et al. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?. Mol Imaging Biol 10 1 (2008) 62-66
6. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18 20 (2000) 3495-3502
7. Shimoda W., Hayashi M., Murakami K., et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 14 3 (2007) 260-268
8. Tchou J., Sonnad S., Bergey M.R., et al. Degree of tumor FDG uptake correlates with proliferation index in triple-negative breast cancer. Mol Imaging Biol (2009) [Epub ahead of print]
9. Bos R., van Der Hoeven J.J., van Der Wall E., et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
10. Burgman P., O'Donoghue J.A., Humm J.L., et al. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 42 (2001) 170-175
11. Tseng J., Dunnwald L.K., Schubert E.K., et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 11 (2004) 1829-1837
12. Grover-McKay M., Walsh S.A., Seftor E.A., et al. Role for glucose transporter 1protein in human breast cancer. Pathol Oncol Res 4 (1998) 115-120
13. Brown R.S., Goodman T.M., Zasadny K.R., et al. Expression of hexokinase II and glut-1 in untreated human breast cancer. Nucl Med Biol 29 (2002) 443-453
14. Brown R.S., Leung J.Y., Fisher S.J., et al. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between glut-1 expression and FDG uptake. J Nucl Med 37 (1996) 1042-1047
15. Brown R.S., and Wahl R.L. Overexpression of glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 72 (1993) 2979-2985
16. Rogers S., Macheda M.L., Docherty S.E., et al. Identification of a novel glucose transporter-like protein-glut-12. Am J Physiol Endocrinol Metab 282 (2002) E733-E738
17. Macheda M.L., Rogers S., and Bets J.D. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol 202 (2005) 654-662
18. Kumar R., Loving V.A., Chauhan A., et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 46 11 (2005) 1819-1824
19. Mavi A., Urhan M., Yu J.Q., et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 47 9 (2006) 1440-1446